“…Oral malignant melanomas are extremely rare lesions and occur commonly in the maxillary gingiva more frequently on the palate with fewer incidences in the mandibular gingiva. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Herein, we investigated the morphological plasticity of tumor cells with special focus on vasculogenic mimicry and neovascularisation in human melanoma and mouse xenografts of human melanoma cell lines. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Metastatic melanoma is the most aggressive form of skin cancer with a median overall survival of less than one year. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The diagnosis and management of primary cutaneous melanoma have traditionally relied on clinical and histological characteristics. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Cutaneous malignant melanomas share a number of molecular attributes such as limitless replicative potential that define capabilities acquired by most malignancies. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Uveal melanoma (UM) is the most prevalent intraocular malignant tumor in the Western world. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…If a damaged MSC or melanocyte precursor can be shown to be the primary origin of melanoma, targeted identification and eradication of it by antibody-based therapies will be the best method to treat melanoma and a very effective way to prevent its recurrence. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Primary melanoma of the lung is an extremely rare pathological entity and sparsely reported in the literature. …”
Enlace del recurso
Enlace del recurso

“…BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: To report the tumor, patient, and treatment characteristics of long-term metastatic uveal melanoma survivors. METHODS: A non-comparative, retrospective case series of patients from a single institution surviving >24 months with metastatic uveal melanoma (UM). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In recent years, rapid advances were reached in the understanding of a series of biologic signals influencing cutaneous malignant melanoma (CMM) cells. CMM is in close contact with a peculiar dermal extracellular matrix (ECM). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Here we report extensive melanosis and melanoma (skin cancer) in wild populations of an iconic, commercially-important marine fish, the coral trout Plectropomus leopardus. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…However, in the case of melanoma, little information is available to what extent cellular bioenergetics processes contribute to the progression of the disease and related to it, whether oxidative phosphorylation (OXPHOS) has a prominent role in advanced melanoma. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We will go through the different phases of this phenomenon, exposing the most relevant evidences obtained from experimental models and human clinical data, with special focus on Cutaneous Melanoma, an immunogenic tumor per excellence. We will describe the different immunotherapeutic strategies employed and consider current models accounting for tumor heterogeneity. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Identification of melanoma patients at high risk for recurrence and monitoring for recurrence are critical for informed management decisions. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This study unravels the molecular mechanisms by which melanomas disarm NK cells and offers clues to revert such inhibitory effect.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Donor transmission of melanoma is one of the more common and lethal of recipient malignancies, often presenting with systemic disease. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The purpose of this study is to review the development of BRAF inhibitors, with emphasis on the trials conducted with dabrafenib (GSK2118436) and the evolving role of dabrafenib in treatment for melanoma patients. Fifty percent of cutaneous melanomas have mutations in BRAF, resulting in elevated activity of the mitogen-activated protein kinase signaling pathway. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso